Journal Information
Vol. 60. Issue S2.
Lung cancer: New perspectives
Pages S4-S12 (October 2024)
Share
Share
Download PDF
More article options
Vol. 60. Issue S2.
Lung cancer: New perspectives
Pages S4-S12 (October 2024)
Original Article
When to Consider Invasive Lymph Node Staging in Non–Small-Cell Lung Cancer? A Novel Scoring System Utilising Metabolic Parameters in 18F-FDG PET/CT
Visits
775
Figen Öztürk Ergüra, Ayperi Öztürka,
Corresponding author
drayperi@gmail.com

Corresponding author.
, Özlem Özdağa, Ebru Tatcıb, Özlem Özmenb, Aydın Yılmaza
a Health Sciences University, Atatürk Sanatoryum Education and Research Hospital, Interventional Pulmonology, Ankara Turkey
b Health Sciences University, Etlik City Hospital, Nuclear Medicine, Ankara Turkey
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (5)
Table 1. Characteristics of patients.
Table 2. Results of univariate and multivariate logistic regression analyses in predicting LN metastasis.
Table 3. Cut-off values and diagnostic accuracy of LN size, SUVmax, MTV and TLG measurements in predicting LN metastasis.
Table 4. Distribution of data included in the scoring system.
Table 5. Analysis of the scoring system for predicting LN metastasis.
Show moreShow less
Special issue
This article is part of special issue:
Vol. 60. Issue S2

Lung cancer: New perspectives

More info
Abstract
Objective

The maximum standardised uptake value (SUVmax) is a widely utilised metric in positron emission tomography/computed tomography for clinically staging non–small-cell lung cancer (NSCLC), yet the reliability of SUVmax remains controversial. We herein aimed to assess the effectiveness of semi-quantitative parameters, encompassing size, SUVmax, metabolic tumour volume (MTV), total lesion glycolysis (TLG) and heterogeneity factor (HF), in evaluating both primary tumours and lymph nodes (LNs) on positron emission tomography/computed tomography. A novel scoring system was devised to appraise the role of semi-quantitative parameters and visually evaluate LNs for nodal staging.

Materials and Methods

Patients with pathological NSCLC, diagnosed between 2014 and 2019 and clinically staged I-III, were enrolled in the study. Patient demographics, including age, sex, tumour location, diameter, tumour-node-metastasis stage, as well as SUVmax, MTV, TLG and HF parameters of primary tumours and LNs, were documented.

Results

The analysis comprised 319 patients and 963 LNs. Patients had a mean age of 61.62 years, with 91.5% being male. Adenocarcinoma exhibited a histological association with LN metastasis (P=0.043). The study findings revealed that tumour size, SUVmax, MTV, TLG and HF did not significantly affect the detection of LN metastasis. Conversely, non-squamous cell carcinoma, LNs exhibiting higher FDG levels than the liver, LN size, SUVmax, MTV and TLG were identified as risk factors (P<0.0001). The identified cut-off values were 1.05cm for LN size, 4.055 for SUVmax, 1.805cm3 for MTV and 5.485 for TLG. The scoring system incorporated these parameters, and visual assessment indicated that a score of ≥3 increased the risk of metastasis by 14.33 times.

Conclusion

We devised a novel scoring system and demonstrated that LNs with a score of ≥3 in patients with NSCLC have a high likelihood of metastasis. This innovative scoring system can serve as a valuable tool to mitigate excessive and extreme measures in the assessment of invasive pathological staging.

Keywords:
NSCLC
Mediastinal staging
MTV
SUVmax
TLG

Article

These are the options to access the full texts of the publication Archivos de Bronconeumología
Member
If you are a member of SEPAR:
  • Go to >>>SEPAR<<< website and sign in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Archivos de Bronconeumología

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?